U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT07451665) titled 'Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis' on Feb. 28.
Brief Summary: This is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Takayasu Arteritis (TAK)
Intervention:
DRUG: Vanakizumab
Vanakizumab 240mg each 4 weeks taken subcutaneously with an additional injection at day 15
DRUG: Ivarmacitinib
Ivarmacitinib 8mg daily taken ora...